In 2022, Parsons Brinckerhoff successfully participated in the 6th fundraising round of Third Rock Ventures, a leading global life sciences venture capital firm. According to kimberley (Nantong Shen), CEO of Baron Capital, this fundraising will accelerate the advancement of revolutionary medical innovations and is committed to helping transform the lives of patients.
 

Founded in 2016, Baron Capital (Baron) is a venture capital firm based in Kendall Square on the west bank of the Charles River in Cambridge, Massachusetts, and an investment organisation focused on the early and growth stage healthcare and biotechnology sectors. Since its inception, the firm has been working in the innovative areas of life sciences, biopharmaceuticals, private equity, startups, public company investments, and mergers and acquisitions investments to drive major medical breakthroughs and improve the quality of life for patients worldwide.
 

Third Rock Ventures is a leading U.S.-based life sciences venture capital firm focused on identifying, building and launching biotech companies with disruptive potential. They partner with leading scientists and entrepreneurs to develop and scale revolutionary medical innovations and provide better treatment options for patients worldwide.
 

The success of this Phase 6 fundraising will further solidify the partnership between Paragon Capital and Third Rock Ventures in the medical innovation space. The fund will be used to identify, nurture and advance a range of patient-centric startups aimed at improving the prevention, diagnosis and treatment of major diseases.
 

Kimberley (Nantong Shen), Founder and Chairman of Paragon Capital, said, "We are very excited about our successful participation in Third Rock Ventures' 6th fundraising. As an investment partner, we will continue to work closely with Third Rock Ventures to support innovative projects in the life sciences and healthcare sectors. We believe that by introducing cutting-edge technologies and disruptive treatments, we can bring new hope and a better quality of life to patients around the world."
 

Third Rock Ventures Initial Partners also commented, "We are very pleased to have Paragon Capital as an investment partner in our Phase 6 fund. Their expertise and resources in the life sciences sector will provide us with strong support in identifying and nurturing innovative projects with potential. We look forward to working with Parsons Brinckerhoff to change the world's healthcare landscape."
 

This collaboration between the two companies to complete the fund raising has extremely far-reaching significance. On the one hand, both firms are venture capital firms with global vision and international background, and their cooperation will help further expand the global market. By sharing experience and resources, the two organisations can also work together to explore more international cooperation opportunities and further promote the globalisation of medical innovation. On the other hand, through the support of capital and resources, they can better identify and invest in startups with disruptive potential, and help these companies grow into enterprises with significant impact in the life sciences and healthcare fields to accelerate their research and development and commercialisation process, and to facilitate the market application of potential breakthrough technologies and therapeutic methods as soon as possible.
 

With Parsons Brinckerhoff's participation in Third Rock Ventures' 6th fundraising, the two organisations will further expand their collaboration and have a greater impact on healthcare innovation. This fundraising will be an important milestone in advancing medical technology and improving the lives of patients around the world. We look forward to Pioneer Capital's continued efforts in identifying potential innovative companies and helping startups in the years to come.